Brief: Mauna Kea Technologies Says CONTACT 2 Study Met Its Clinical Endpoints
Nov 6 (Reuters) - MAUNA KEA TECHNOLOGIES SAS MKEA.PA :
* PIVOTAL STUDY ON CONTACT 2 PANCREATIC CYSTS HAS MET ALL OF
ITS
PRIMARY AND SECONDARY CLINICAL ENDPOINTS
* SIGNIFICANTLY HIGHER DIAGNOSTIC PERFORMANCE OF CELLVIZIO
COMPARED TO THE STANDARD TECHNIQUE
* CELLVIZIO MADE A CONCLUSIVE AND CORRECT DIAGNOSIS IN 21 OF
THE
23 PATIENTS
Source text for Eikon: ID:nBw51KPwVa
Further company coverage: MKEA.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Mauna Kea Technologies SA
See all newsBrief: Mauna Kea Technologies Confirms Trajectory Toward Profitability By Year-End 2027
Brief: Mauna Kea Technologies Announces Results Of Its Combined General Meeting
French and Benelux stocks-Factors to watch 21 Nov
Brief: Mauna Kea Technologies Receives NMPA Regulatory Approval In China For Its Next-Generation Cellvizio Platform
Europe Research Roundup: Craneware, Croda, Genus